Ildong’s new GLP-1 analogue starts clinical trial

Ildong Pharmaceutical new oral diabetes and obesity treatment candidate

MFDS approves IND for ID110521156

Pic of Ildong Pharmaceutical

Ildong Pharmaceutical announced on the 6th that it recently received investigational new drug (IND) approval from the Ministry of Food and Drug Safety for its ID110521156’s Phase I clinical trial.

 

ID110521156 is Ildong’s new GLP-1 receptor agonist drug candidate.

 

Through the trial, the company plans to evaluate the tolerability, safety, and pharmacokinetic properties of ID110521156 in healthy adults.

 

ID110521156 acts as an analog of the GLP-1 hormone, which regulates blood sugar levels by inducing insulin secretion in the body.

 

GLP-1 hormone is produced in pancreatic beta cells and is known to be involved in insulin synthesis and secretion in the body, reduction of blood sugar level, regulation of gastrointestinal motility, and appetite suppression.

 

Based on the clinical development and commercialization progress, the company plans to develop ID110521156 into an oral new drug targeting type 2 diabetes and obesity in the future.

 

ID110521156 is a new compound that serves the same function as the GLP-1 hormone.

 

Compared to biological agents such as peptides, it has a low molecular weight and is structurally stable.

 

In an efficacy and toxicity evaluation of ID110521156 that was conducted using diseased animal models, the drug candidate has demonstrated superior efficacy in insulin secretion and glucose control, as well as superior safety compared to other same-class competitors.

 

Ildong Pharmaceutical plans to develop an oral formulation that has advantages in terms of marketability and dosing convenience, unlike existing injection-type formulations, by utilizing the differences in effectiveness, safety, and stability resulting from the structural characteristics of its active substance.

 

An official from Ildong Pharmaceutical said, “We have been actively discussing partnership opportunities with many global pharmaceutical companies, including licensing out our technology.

 

To secure a favorable position in terms of promoting commercialization and securing rights, we have completed patent registration or applications in major market countries including Korea, the United States, Europe, China, and Japan.”